Korean J Med.  2002 May;62(5):513-521.

Changes of plasma interleukin-1 receptor antagonist, interleukin-8 and other serologic markers during chemotherapy in patients with active pulmonary tuberculosis

• Lee JH
• Chang JH

Abstract

BACKGROUND
The human immune response to Mycobacterium tuberculosis is mediated by macrophage and T-lymphocyte. The alveolar macrophage phagocyting mycobacterium produced interleukin (IL)-1 as an inflammatory mediator and IL-8 as a cytokine for leukocyte recruitment and granuloma formation. Interleukin-1 receptor antagonist (IL-1ra) is an internal antagonist of IL-1.
METHODS
Plasma levels of IL-1ra and IL-8 and other serologic markers were measured in 18 patients with active tuberculosis before treatment and after 2 months and 6 months of treatment.
RESULTS
During treatment with antituberculous medication, patients showed significant changes of hemoglobin, hematocrit, white blood cell (WBC), platelet counts, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), ferritin and plasma IL-1ra. After 2 months of treatment, ESR and CRP were significantly diminished as compared with those before treatment. After 6 months of treatment, hemoglobin was increased and WBC, platelet counts, ESR, CRP and ferritin decreased significantly as compared with those before treatment. At each point of observation the group of delayed therapeutic response showed lower body weight, hemoglobin and hematocrit and higher WBC, platelet counts, ESR, IL-8 and IL-1ra than those of early responsive group. During the time course of treatment, significant differences were observed in body weight, body mass index, hemoglobin, hematocrit, WBC, platelet counts, ESR, CRP and ferritin for each group of early and delayed response.
CONCLUSION
Plasma concentrations of IL-1ra and IL-8 might indirectly reflect their different patterns of secretion and functions with different peaks during the course of treatment and they seemed not so sensitive as other inflammatory markers to evaluate the disease activity during antituberculous treatment. However, IL-1ra can be considered a marker of disease activity and response of treatment.

Keyword

Tuberculosis; Receptor Antagonist Interleukin-1; Interleukin-8

MeSH Terms

Blood Sedimentation
Body Mass Index
Body Weight
C-Reactive Protein
Drug Therapy*
Ferritins
Granuloma
Hematocrit
Humans
Interleukin 1 Receptor Antagonist Protein
Interleukin-1*
Interleukin-8*
Interleukins
Leukocytes
Macrophages
Macrophages, Alveolar
Mycobacterium
Mycobacterium tuberculosis
Plasma*
Platelet Count
T-Lymphocytes
Tuberculosis
Tuberculosis, Pulmonary*
C-Reactive Protein
Ferritins
Interleukin 1 Receptor Antagonist Protein
Interleukin-1
Interleukin-8
Interleukins